Рак лёгких

First-in-Human: Jyoti Malhotra, MD, MPH on Phase I Trials, Lung Cancer in 2026, and Yale

First-in-Human: Jyoti Malhotra, MD, MPH on Phase I Trials, Lung Cancer in 2026, and Yale OncLive

Stage 3 Lung Cancer Injection Before Radiation: What Patients Need to Know

Stage 3 Lung Cancer Injection Before Radiation: What Patients Need to Know Cure Today

Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer

Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer HMP Global Learning Network

Young, Healthy, and Facing Stage 4 Lung Cancer

Young, Healthy, and Facing Stage 4 Lung Cancer American Lung Association

WCLC 2026: The lung cancer drug development readouts that caught our eye

WCLC 2026: The lung cancer drug development readouts that caught our eye Labiotech.eu

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer BioSpace

Rare inherited EGFR mutation linked to dramatically increased lung cancer risk

A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute. The findings included de-identified, aggregated genetic data from more than 3.3…

Altis Labs AI Imaging Endpoint Predicts Overall Survival Benefit in Phase 3 Lung Cancer Trial: Data Presented at IASLC WCLC 2026

Altis Labs AI Imaging Endpoint Predicts Overall Survival Benefit in Phase 3 Lung Cancer Trial: Data Presented at IASLC WCLC 2026 BioSpace

Ivonescimab Topped Keytruda on Median Lung Cancer Survival by Eight Months in China but Lacks U.S. Approval

Ivonescimab Topped Keytruda on Median Lung Cancer Survival by Eight Months in China but Lacks U.S. Approval Medical Daily

First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled

First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled Medical Daily

Improving Lung Cancer Biomarker Education in Black Communities

Improving Lung Cancer Biomarker Education in Black Communities Cancer Nursing Today

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy MedPage Today

World-renowned lung cancer expert faces the disease he has spent decades treating

World-renowned lung cancer expert faces the disease he has spent decades treating UCHealth

Health Rounds: New dye for MRI exams detects lung cancer earlier

Health Rounds: New dye for MRI exams detects lung cancer earlier whbl.com

WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?